A Phase IIIb, Randomized, Multicenter, Parallel-group, Non-inferiority, Open-label Study Evaluating the Efficacy, Safety, and Tolerability of Long-acting Cabotegravir Plus Long-acting Rilpivirine Administered Every 8 Weeks or Every 4 Weeks in HIV-1-infected Adults who are Virologically Suppressed

Trial Profile

A Phase IIIb, Randomized, Multicenter, Parallel-group, Non-inferiority, Open-label Study Evaluating the Efficacy, Safety, and Tolerability of Long-acting Cabotegravir Plus Long-acting Rilpivirine Administered Every 8 Weeks or Every 4 Weeks in HIV-1-infected Adults who are Virologically Suppressed

Recruiting
Phase of Trial: Phase III

Latest Information Update: 09 Dec 2017

At a glance

  • Drugs Cabotegravir (Primary) ; Cabotegravir (Primary) ; Rilpivirine (Primary) ; Rilpivirine (Primary)
  • Indications HIV-1 infections
  • Focus Therapeutic Use
  • Acronyms ATLAS-2M
  • Sponsors ViiV Healthcare
  • Most Recent Events

    • 27 Nov 2017 According to a ViiV Healthcare media release, approximately half of the participants in this trial will rollover from the ongoing ATLAS trial (CTP 700277865; NCT02951052).
    • 27 Nov 2017 According to a ViiV Healthcare media release, initial results from this trial are anticipated in 2019.
    • 20 Nov 2017 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top